Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD

Published: Jan 05, 2010

NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY).

Back to news